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Background: Research conducted before the introduction of anti-retroviral therapy
(ART), showed that the majority of children living with HIV (CLHIV) would die before their
second birthday. In Zambia, ART was rolled out to the public health system in 2004 with
subsequent improved survival in CLHIV. However, the survival rates of CLHIV on ART
in Zambia since 2004 have not been extensively documented. We assessed survival
experiences and the factors associated with survival in CLHIV on ART in Zambia.
Methods: We conducted a retrospective cohort analysis of CLHIV (aged up to 15
years) using routinely collected data from health facilities across Zambia, over 13 years
to ascertain mortality rates. We explored survival factors using Cox regression giving
adjusted hazard ratios (AHR) and 95% confidence intervals (95% CI). Nelson Aalen
estimates were used to show the cumulative hazards of mortality for different levels of
explanatory factors.
Results: A total of 65,448 eligible children, were initiated on ART between 2005 and
2018, of which 33,483 (51%) where female. They contributed a total survival time of
275,715-person years at risk during which 3,265 children died which translated into an
incidence rate of 1.1 deaths per 100 person-years during the review period. Mortality
rates were highest in children in the first year of life (Mortality rate 2.24; 95% CI =
2.08–2.42) and during the first year on ART (Mortality rate 3.82 95% CI = 3.67–3.98).
Over 50% of the children had been on ART for 5–10 years by 2018, and they had the
lowest risk of mortality compared to children who had been on ART for <5 years.
Conclusions: Children with HIV in Zambia are surviving much longer than was predicted
before ART was introduced 14 years ago. This key finding adds to the literature on
analysis of survival in CLHIV in low income settings like Zambia. However, this survival
is dependent on the age at which ART is initiated and the time on ART highlighting the
need to increase investments in early infant diagnosis (EID) to ensure timely HIV testing
and ART initiation for CLHIV.
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INTRODUCTION
UNAIDS has a target to end all new HIV infections by 2030,
but in 2018 there were still 1.7 million children living with HIV
(CLHIV) (1). Worldwide, every year there are 110,000 deaths
in CLHIV under the age of 15 years, and 180,000 new HIV
infections from mother to child transmission (1, 2). In Zambia,
in 2018 there were ∼62,000 children living with HIV, 79% of
them were on ART and there were 3,000 AIDS related annual
deaths (3, 4). Without ART, more than 50% of children infected
with HIV will die before their second birthday (5, 6). From its
inception ART has been shown to reduce mortality among adults
and children living with HIV more than 50% since the year 2000
(7–9). With the roll out of HIV treatment services, the initiation
of CLHIV on ART in Zambia increased steadily from 24,000 in
2010 to 49,116 in 2018 (2, 3). This translated into a reduction in
HIV-related mortality from 3,600 in 2016 to 3,000 in 2018 (3, 4).
However, studies show that mortality among CLHIV on ART
continues to be high, especially among infants with advanced
disease, and in the first 12 months following ART initiation
despite the use of prevention of mother-to-child transmission of
HIV (PMTCT) drugs (10, 11). Studies have shown that initiating
children on ART early (birth-7 weeks) reduced mortality by 76%
compared to postponing ART until progression to advanced HIV
disease or CD4 count thresholds are reached (11, 12). However,
other studies have shown that WHO clinical stage 3 or 4 and
young age at the time of ART initiation were associated with
a 5-fold increased risk of death, while absolute CD4 counts of
<350 cells/mm3 at ART initiation and underweight (weight-
for-age Z-score <-2) were associated with 3.6 and 3,5 times
increase in mortality among CLHIV (5, 13–15). In addition,
overall mortality rates among CLHIV on ART vary from country
to country depending on several factors. In a 7-year study in
South Africa, a mortality rate of 4.7 per 100 person-years was
reported (16), whereas in Ethiopia a mortality rate of 1.2 per
100 person-years was reported in Addis Ababa and 2.1 per 100
person-years in Eastern Ethiopia after a 2 year follow up (14).
Furthermore, a mortality rate of 3.0 per 100 person-years was
reported in a 1 year follow up study in Nigeria (17).
Despite the variedmortality rates, CLHIV are surviving longer
on ART. Studies in Asia and Africa have shown survival rates
that ranged from 84 to 97% after 12 months of ART for children
initiated on ART at a median age of 5–7 years. Another multi
country study in Africa also reported above 90% (93%) survival
rates after 2 years of follow up on ART (18). There is limited
global data on long term survival of children on ART. In Zambia
the long-term survival of CLHIV and clinical factors that are
associated with patterns of survival have not been extensively
documented. We therefore assessed the probability of survival
and factors associated with mortality among CLHIV in Zambia.
MATERIALS AND METHODS
Study Population and Sample
This study was a quantitative retrospective cohort study of
CLHIV with records in the Zambian SmartCare data. SmartCare
is an electronic patient monitoring system which is used in
about 600 government health facilities in all districts in Zambia
(19). The system records patient characteristics with a unique
identification number, at the first contact with the clinic, and
then records clinical information at each subsequent health
facility visit. A total sampling from the SmartCare records of
all children with a positive HIV result, aged 15 years and
younger at the time of ART initiation, regardless of missing
data during the period under review, was conducted for
this analysis.
Clinical Procedures
In the Zambian health care system, all children with a positive
HIV test result and diagnosis are eligible to receive HIV
care according to national ART prevention and treatment
guidelines. This includes documenting medical history, physical
examination, anthropometric measurements, socio demographic
information, and WHO clinical stage. In addition, measurement
of CD4+ T-cell counts or percentages, hemoglobin levels (HB),
renal, liver function tests, and HIV viral loads are taken.
Eligible children are then treated with a first-line regimen,
either Nevirapine based (NVP), Efavirenz based (EFV), or
Nucleoside reverse transcriptase inhibitors (NRTI). Children
are then asked to return for clinical evaluation every 3
months (20, 21).
Data Definitions and Statistical Methods
Follow up of children started at the date they initiated ART,
and continued until death, or the date of censoring. The
event of interest, death was coded as 1 for those who died,
and 0 for those who were censored. The date of censoring
(end date) contained the date of death for those that died,
and the last clinic date for those who were lost to follow
up, with all other children censored on 1st January 2018, or
the date of their 15th birthday, whichever came first. The
variable age at ART initiation was obtained by subtracting
the child’s date of birth from the date of ART initiation and
was categorized into 5 age bands (birth to <1 year, 1–2, 3–
5, 6–9, and 10–15 years). Time on ART was divided into
4 points that is at 1, at 2, at 5, and at 10 years on ART.
Children’s weight was used to calculate the weight for age
Z-scores (WAZ) for children in the dataset using a WHO
standard (22).
Categorical variables were summarized across all children
as frequencies and percentages. Mortality rates were defined as
the number of deaths divided by the person-years of follow-
up with 95% confidence intervals (95% CI) for mortality
rates defined for each subgroup of children. Nelson Aalen
cumulative Hazards were used to graphically show the differences
in mortality by subgroups of children. A modified Cox
regression model, adjusting for possible heterogeneity at the
facility level, was used to obtain hazard ratios (HR) and
95% confidence intervals (95% CI) for factors associated
with mortality, with subsequent adjustment for sex, age
at ART initiation, and province to obtain adjusted HR
(aHR) and 95% CI. In order to model the unobserved
covariates at health facility level, an additional parameter,
theta, drawn from a Gamma distribution, was estimated in
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the modified Cox regression model, representing the frailty
or variation in the log of the survival function across
health facilities.
For socio-demographic variables, such as age, sex, year, health
facility and province, a complete case analysis was conducted,
using all the children, assuming the small amount of missing data
were missing at random. The results present the crude analysis,
the age-adjusted analysis and the frailty model that adjusts for
the effect of clustering. For variables where a large number
of children had missing data, a subset analysis on children
TABLE 1 | Background characteristics of CLHIV on ART in Zambia from 2004 to 2018.
Characteristic Child status Person years of follow up Mortality rates (95% CI)
Number of children that died Total number of children analyzed
Overall 3,265 65,448 (100) 275,715 0.011 (0.011–0.012)
Sex
Female 1,520 33, 483 (51) 138,737 0.80 (0.65–0.99)
Male 1,745 31,965 (49) 137,045 1.08 (0.90–1.30)
Age when starting ART
Birth – <1 year 675 6,311 (10) 30,000 2.24 (2.08–2.42)
1–2 years 1,211 14,925 (23) 73,864 1.63 (1.54–1.73)
3–5 years 432 12,073 (18) 65,278 0.66 (0.60–0.791)
6–9 years 513 15,479 (23) 70,671 0.72 (0.66–0.79)
10–15 years 431 16,496 (25) 35,687 1.20 (1.09–1.32)
WHO clinical staging
Stage 1 920 39,886 (71) 186,156 0.49 (0.46–0.52)
Stage 2 334 5,499 (10) 22,216 1.50 (1.35–1.67)
Stage 3 1,150 8,406 (15) 32,032 3.38 (3.38–3.80)
Stage 4 425 1,961 (4) 7,267 5.84 (5.31–6.43)
CD4 count
Normal 49 1,362 (30) 7,779 0.62 (0.47–0.83)
Low 53 3,246 (71) 13,612 1.12 (0.95–1.31)
Weight for age Z-score
Normal 130 5,261 (93) 37,455 0.341 (0.29–0.41)
Moderate 29 195 (3) 1,101 2.63 (1.82–3.78)
Severe 18 145 (3) 760 2.36 (1.49–3.75)
ART regimen
NRTI 601 7,314 (47) 23,700 1.38 (0.78–2.44)
EFV Based 137 3,580 (23) 15,471 1.19 (0.66–2.15)
NVP based 418 4,393 (29) 8,683 4.11 (2.68–6.30)
Year of ART initiation
2004/2006 473 6,035 (9) 35,904 1.31 (1.20–1.44)
2007/2009 1,243 16,445 (25) 93,977 1.32 (1.25–1.39)
2010/2012 1,003 19,026 (29) 87,213 1.15 (1.08–1.22)
2013/2015 470 17,549 (26) 51,629 0.91 (0.83–0.99)
2016/2017 76 6,393 (10) 6,991 1.08 (0.86–1.36)
Time on ART
Under 1 year 2,265 11,276 (17) 59,206 3.82 (3.67–3.98)
At 1 year 430 7,856 (12) 50,211 0.85 (0.77–0.94)
At 2 years 445 22,132 (33) 104,156 0.42 (0.38–0.46)
At 5 years 123 21,614 (33) 59,543 0.20 (0.17–0.24)
At 10 years 2 2,570 (4) 2,598 0.07 (0.01–0.30)
Time from testing to ART initiation
Same day 1,075 21,307 (33) 86,961 1.23 (1.16–1.31)
1 week 240 3,712 (6) 15,426 1.55 (1.37–1.76)
Up to 1 month 849 13,471 (21) 56,774 1.49 (1.39–1.59)
More than a month 1,101 26,958 (41) 116,553 0.94 (0.89–1.00)
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TABLE 2 | Hazard ratios for CLHIV on ART by province and facility types in Zambia.
Characteristic Number of Health
facilities
Person years of follow
up
Number of deaths Mortality rates per 100
(95% CI)
Unadjusted Hazard
ratios
(CI)*
Adjusted Hazard Ratios
(CI)**
Total 404 275,715 3,265 0.011 (0.011–0.12) – –
Province
Central 41 24,921 207 0.83 (0.72–0.95) 1 1
Luapula 26 10,753 174 1.61 (1.39–1.87) 1.78 (1.45–2.17) 1.60 (1.30–.95)
Copperbelt 98 63,448 603 0.95 (0.87–1.02) 1.05 (0.92–1.23) 1.11 (0.95–1.31)
Eastern 41 25,186 376 1.49 (1.34–1.65) 1.51 (1.27–1.79) 1.58 (1.33–1.88)
Lusaka 68 64,830 797 1.22 (1.14–1.31) 1.25 (1.07–1.46) 1.36 (1.17–1.59)
Muchinga 14 3,814 81 2.12 (1.70–2.64) 1.84 (1.42–2.38) 1.95 (1.50–2.50)
North western 22 10,938 205 1.87 (1.63–2.14) 2.06 (1.70–2.50) 2.05 (1.69–2.49)
Northern 28 8,963 145 1.61 (1.37–1.90) 1.55 (1.25–1.91) 1.56 (1.26–1.93)
Southern 101 41,190 462 1.12 (1.02–1.22) 1.26 (1.07–1.48) 1.28 (1.10–1.51)
Western 60 21,667 215 0.99 (0.86–1.13) 1.16 (0.96–1.40) 1.18 (0.97–1.42)
Facility type
Hospital 103 140,270 1,542 1.09 (1.04–1.15) 1 1
Health center 292 133,904 1,709 1.27 (1.21–1.33) 1.01 (0.95–1.09) 1.07 (0.98–1.15)
Health post 6 402 2 0.49 (0.12–1.98) 0.25 (0.06–1.01) 0.27 (0.06–1.11)
District type
Rural 522 237,321 2,770 1.16 (1.12–1.21) 1 1
Urban 239 38,394 495 1.28 (1.18–1.40) 1.14 (1.03–1.25) 1.08 (0.97–1.20)
*Tested using Cox proportional Hazards ratio.
**Adjusted for adjusted for age at ART start, sex and province.
with valid data was performed to assess the mortality risks for
those variables.
RESULTS
A total of 70,718 children were recorded as having been initiated
on ART from 496 health facilities and 71 districts across Zambia
during the period under review. Of these only 65,448 were
analyzed in survival analysis translating to 33,483 (51%) female,
and 31,965 (49%) male.
The largest proportion of children analyzed were between
10 and 15 years and these accounted for about 25% of the
sample while the smallest proportion was accounted for by
children under 1 year of age at 10%. Mortality was also highest
among children that initiated ART under 2 years, and lowest
among children that initiated ART at older ages (10–15 years).
Children that initiated ART during the period under review, were
largely initiated on NRTIs (47%) and NVP based regimen (29%)
(Table 1).
Health Facility and Provincial
Characteristics of CLHIV on ART
Out of the three levels of health facilities that were analyzed,
hospitals and health centers accounted for the highest number
of person years of follow-up (140,270 and 133,904, respectively)
with health posts having the lowest person years of follow up
(402). Out of the 3,265 children that died, hospitals in the
country accounted for about 1,542 deaths translating to about
47% of deaths recorded during the reporting period. On the
other hand, facilities in Lusaka (812, 24%), Copperbelt (583, 18%)
and Southern (467, 14%) provinces had the highest number of
deaths amongst all the ten provinces while facilities in Muchinga
province had the lowest number of deaths with 81 deaths (2.5%).
Children in Muchinga, Luapula and North western provinces
also had the lowest chances of survival compared to children in
Central province (North western, aHR 2.05 95% CI = 1.69–2.4;
Muchinga, aHR1.95 95% CI= 1.50–2.50; Luapula, aHR 1.60 95%
CI= 1.30–1.95) (Table 2).
Survival of CLHIV on ART and Associated
Factors
A total of 65,448 children were analyzed using proportional
hazards survival analysis, with a total of 275,715 person-years
at risk. The individual children had follow-up times that ranged
from 1 month to 13.5 years. Survival of children on ART
was highest among children who initiated ART between 10
and 15 years, with these children having 72% lower hazard
ratio compared to children initiating ART between birth and 1
year (aHR 0.28,95% CI = 0.25–0.32). There was considerable
variability in survival amongst the children initiating ART
from the different provinces (Table 2). Factors associated with
mortality included age when initiating ART and time on ART
although these two variables were correlated as only children who
initiated ART at younger ages could have a longer duration on
ART. Compared to children who were diagnosed and initiated
ART in the first year of life, children initiating ART between
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TABLE 3 | Multi-level Proportional hazard ratios for factors associated with
mortality among CLHIV on ART in Zambia.
Characteristic Unadjusted
Hazard ratios
(CI)*
Adjusted Hazard
Ratios (CI)**
Adjusted Hazard ratios
(Clustering at health
facility level) (CI)***
Sex
Female 1 1 1
Male 1.18 (1.11–1.27) 1.17 (1.09–1.25) 1.14 (1.06–1.23)
Age when starting ART
Birth−1 year 1 1 1
1–2 years 0.74 (0.67–0.81) 0.74 (0.67–0.81) 0.68 (0.61–0.75)
3–5 years 0.31 (0.34–0.41) 0.31 (0.27–0.35) 0.35 (0.31–0.40)
6–9 years 0.29 (0.27–0.35) 0.29 (0.26- 0.33) 0.39 (0.34–0.45)
10–15 years 0.28 (0.26–0.33) 0.28 (0.25–0.32) 0.56 (0.48–0.64)
WHO clinical staging
Stage 1 1 1 1
Stage 2 2.86 (2.52–3.24) 2.92 (2.58–3.31) 4.11 (3.60–4.68)
Stage 3 6.96 (6.38–7.59) 6.25 (5.72–6.82) 10.6 (9.70–11.74)
Stage 4 11.6 (10.4–13.0) 9.53 (8.48–10.72) 16.4 (14.56–18.67)
Time from testing to ART initiation
Same day 1 1 1
One week 1.27 (1.10–1.46) 1.24 (1.08–1.43) 1.19 (1.01–1.39)
Up to 1 month 1.22 (1.12–1.34) 1.27 (1.16–1.39) 1.39 (1.24–1.55)
More than a
month
0.77 (0.71–0.84) 0.89 (0.81–0.97) 1.18 (1.06–1.32)
*Tested using Cox proportional Hazards ratio.
**Hazards adjusted for age at ART start and sex.
***Frailty model adjusting for clustering at facility level.
The variability of survival between the health facilities 2.18 (95% CI 1.86–2.63).
the first and the second years of life were 32% less likely to
die (aHR 0.68 95% CI = 0.61–0.75), with lower hazard ratios
in each older age group (Table 3). Compared to WHO clinical
stage 1, children with WHO clinical stages 3 (aHR 10.6; 95%
CI = 9.70–11.74) and 4 (aHR 16.49 95% CI = 14.56–18.67)
had increased mortality (Table 3). The frailty coefficient was >0,
showing that the survival rates differed by a factor of 2.18 across
the health facilities.
Three separate models were used restricting the analysis to
subsets of children with data for CD4 counts at initiation, WAZ
and the first line drug regime used at ART initiation. All models
were adjusted for sex, WHO clinical stage, and time on ART,
and the estimates for these variables were similar to the full
model although the significance of the effects was greatly reduced
(Table 4). Higher mortality was observed in those who were
severely malnourished (aHR 4.51, 95% CI 2.57–7.92) compared
to those who were not severely malnourished. Higher values
of frailty for the model including malnourishment indicates
the additional clustering of malnourishment in health facilities,
increasing the variability of the survival rates by 3.22 across the
health facilities. In the samemodel, those who initiated ART with
a CD4 count of <500 cells/µl (aHR 1.76, 95% CI 1.22–2.54) had
higher mortality than those who initiated ART with a CD4 count
>500 cells/µl (Table 4).
Estimation of Cumulative Hazards Curves
of Death Among CLHIV on ART
Nelson Aalen cumulative Hazard estimates were analyzed
for factors affecting survival in CLHIV on ART in Zambia
and cumulative Hazard curves were derived. Factors analyzed
included WHO staging, age at ART initiation, ART drug
regimen and weight for age Z-scores. Overall cumulative hazards
increased rapidly between the first and third year of follow
up time across all factors that were estimated. The cumulative
proportions of children who died on NVP based drug regimen
was 15% higher than children who were on NRTI and EFV based
regimen in the first 5 years of follow up time. Similar increases in
mortality were also evident among children that initiated ART in
WHO clinical stage 4, where steady increases of up to 30% were
noticed for close to 10 years of follow up see Figure 1.
DISCUSSION
Our study outlines survival of children on ART over a 13 year
period (2004–2017) in Zambia. Studies in the past showed that
without ART, more than 50% of CLHIV would die before their
second birthday (5). For all children, mortality rates at ART
initiation were high but lower than those reported in CLHIV
prior to ART availability. Overall the SmartCare database showed
3,265 children on ART died during the 13 years, which gave an
overall estimate of 1.1 deaths per 100-person years.
Mortality rates in our study decreased with longer duration
on ART. Mortality rates in children who had been on ART for
5 years or more were only slightly higher than those reported
for HIV negative children in Zambia (23). The overall mortality
rate of 1.1 per 100 person-years reported in this study changed
with duration on ART. In the first year on ART, the mortality
rate was 12 per 100 person-years, which reduced to 8 per 100
person-years between the first and second year, 1.6 per 100
between the second and fifth year, and 0.62 after the fifth year.
Our mortality rates over the first 2 years on ART were higher
than those reported in a 2 year follow up study in Addis Ababa,
Ethiopia (1.2 per 100 person-years), a 1 year follow up study
in Makurdi, Nigeria (3.0 per 100 person-years), and a 2 year
follow up study in Eastern Ethiopia (2.1 per 100 years). However,
our overall mortality rate was lower than those reported in a
7 year South African study (4.7 per 100 person-years) and an
eight-year study in Jos, Nigeria (14, 16, 17). The variation in
mortality rates could be due to larger sample size in our study
compared to other studies used in the comparison. Another
reason could be the year in which the study was conducted as
WHO guidelines being used at that time could have affected
time to ART initiation, drug regimen and in turn mortality
(10, 14).
Children that initiated ART in Lusaka, Copperbelt, and
Southern provinces as well as children that initiated ART in
hospitals and health centers had higher rates of mortality in our
study. Male children on ART in our study had increased risk
of mortality in contrast to findings by Zanoni et al. (15), in a
South African study where female child had increased chances of
mortality compared to their male counterparts. Nonetheless, our
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TABLE 4 | Multi level adjusted and unadjusted hazards ratios for factors associated with mortality among CLHIV on ART in Zambia clustered at facility level.
Characteristic All children Children with data on CD4
count at initiation
Children with data on WAZ
at initiation
Children with data on first
line drug regimen
Total number
analyzed
55,752 4,105 5,543 14,232
Sex
Female 1 1 1 1
Male 1.14 (1.06–1.23) 1.27 (0.1.22–2.54) 1.12 (0.82–1.53) 1.10 (0.96–1.25)
WHO clinical staging
Stage 1 1 1 1 1
Stage 2 4.18 (3.67–4.76) 3.11 (1.81–5.32) 5.88 (3.72–9.30) 7.02 (5.55–8.88)
Stage 3 11.7 (10.6–12.8) 8.12 (5.46–12.0) 10.6 (7.10–15.9) 29.2 (24.6–34.7)
Stage 4 18.7 (16.6–21.2) 13.3 (7.52–2.52) 11.5 (6.16–21.6) 61.9 (50.2–76.3)
CD4 counts
>=350 (Normal) 1
<350 (Low) 1.76 (1.22–2.54)
Weight for AGE—Z-score (WAZ)
Normal 1
Moderate 3.22 (1.98–5.25)
Severe 4.51 (2.57–7.92)
Drug regimen
NRTI based 1
EFV based 0.28 (0.22–0.35)
NVP based 1.17 (1.01–1.36)
Assessment of clustering
Variability of survival
between the facilities
2.18 (1.86–2.63) 2.18 (1.49–4.66) 3.10 (1.97–6.42) 1.77 (1.46–2.34)
All models adjusted for sex and WHO clinical stage clustering at health facility level.
findings are in line with findings by (16) where higher mortality
rates was experienced amongmales (66.7%) than females (33.3%)
as well as in a cohort of HIV uninfected children where male
children had 2% higher mortality than female children sub
Saharan Africa (24).
This study used a modified Cox regression to allow for
differences in survival due to unobserved covariates at facility
level. In these models, the estimated variance of health facility
frailty terms was significantly >0, indicating large variability in
the survival rates across facilities. The coefficient of variation
for mortality across health facilities, showed mortality rates were
more than twice as high (coefficient of variation = 2.18) in some
facilities than the average. This difference could be due to varying
resources in different facilities, training and availability of staff,
and the quality of services. This high inequality needs to be
addressed by the Ministry of Health to ensure equitable services
to reduce HIV mortality for all Zambian CLHIV.
We also found that the risk of mortality was highest among
infants and younger children initiated on ART, which is the
period for highest risk of death for HIV negative children
also. The risk of death reduced with increasing age. This could
be due to non-adherence, sub optimal doses or exposure to
perinatal antiretroviral therapy, which may lead to rapid disease
progression and later death in infants and younger children (25).
Another reason could also be that diagnosing HIV infection
in infants is intricate and this can delay ART initiation in this
age group (26). However, the proportion of children dying in
this study did not account for over 50% of children analyzed in
any age group showing improvements in survival compared to
studies by Mulugeta et al. (5) and Tariro (6). Our study was in
line with Studies in Asia and Africa that showed survival rates
above 50% (84% to 97%) after 12 months of ART for children
initiated on ART at a median age of 5–7 years, as well as another
multi country study in Africa that also reported above 90% (93%)
survival rates after 2 years of follow up on ART (18).
We found late initiation on to ART from time of HIV
testing was predictive of reduced survival. Studies have shown
that late presentation for early infant diagnosis (EID) services
leads to poor prognosis (27, 28). This is also evidenced by
findings of Bolton-Moore et al. (29) in earlier studies in Zambia.
Our findings showed high mortality rates among children that
initiated ART between 1 week and 1 month after HIV diagnosis.
Current WHO guidelines call for same day ART initiation
after HIV diagnosis which gives children the greatest benefit in
survival (30). Our findings are in line with findings in a study
done in South Africa that reported that 64% of deaths occurred
within 3 months of ART initiation (15); a Nigerian study, where
81.3% and 84.4% of deaths occurred in the first 6 months and
within 1 year, respectively (16) and an Ethiopian study that
reported a high number of deaths within the first sixth months
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FIGURE 1 | Nelson Aalen cumulative Hazard estimates.
of starting ART (31, 32). This pattern of increased mortality
could suggest that HIV-infected children presented with poor
immunological or clinical states at ART initiation or that CLHIV
require some time before the benefits of ART are fully realized,
especially when ART is initiated early (13, 18, 33). However, our
study showed reducing mortality with increase in time to ART
initiation above 1 months. This is similar to findings in a 5-year
cohort study in Thailand where children that initiated ART in
infancy had higher risks of mortality compared to children that
initiated ART at older ages (18). The cohorts of children initiating
ART at older ages, probably reflects those who survived with HIV,
and therefore reflect a “survivor effect” of the older children (18).
The SmartCare database showed 3,265 children on ART died
over the 13 years, but some deaths could have been missed
and not reported to the health facility staff. In the SmartCare
data, CD4 counts, weight and ART regime were not routinely
recorded for every child but may only be recorded when
triggered by a clinical event. We did not attempt to impute
these data but instead carried out subgroup analyses in those
children where the data are recorded to assess whether risk
factors differed in the subgroups. The measures of advanced
HIV diseases, low CD4 count, severe acute malnutrition,
and WHO clinical stages 3 and 4 were all associated with
reduced survival and this is seen in our results (13, 15). These
results are consistent with earlier an study in Zambia which
showed that mortality was higher in children with lower WAZ
scores (29).
This study was not without limitations. The main purpose
of the SmartCare data is for clinical care, treatment and follow
up of CLHIV in health facilities where staff are overburdened.
In these busy health care facilities vital information such as
laboratory results and weight were not collected at every visit,
resulting in a large number of missing data, which meant
these factors could not be included in our main analysis
The results for these variables should be interpreted with
caution, as they did not represent all children. However, the
consistency of the demographic risk factors across the sub-
group analysis is encouraging. The SmartCare database may
have missed some deaths when they did not occur at the
health facility, as these might not have been reported, or
entered into the data base, which could underestimate the
mortality in children on ART. Moreover, loss to follow up
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of children initiated on ART is common among children
on ART in Zambia and has been documented in earlier
studies (20, 34).
CONCLUSIONS
Children with HIV in Zambia are surviving much longer
than was predicted before ART was introduced 14 years ago.
This key finding adds to the literature on analysis of survival
in CLHIV in low income settings like Zambia. However,
survival was dependent on the age at which ART was initiated,
the time on ART, type of health care facility used at ART
initiation and the province where services were accessed. This
highlights the need to increase investments in early infant
diagnosis (EID) and make services more equitable across
Zambia to ensure timely HIV testing and ART initiation
for CLHIV.
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